STOCKS TELEGRAPH

Author: ST Staff

  • How Come The CCHWF Stock Shunned Nearly 4% Last Session?

    The share price of Columbia Care Inc (OTC: CCHWF) fell 3.85 percent to $5.0000 on Friday. A total of 832.01K Columbia Care shares were traded, compared with 526.70K Shares on an Average Weekly Basis. As of the pink sheets, there were 342.63M outstanding shares compared to 80.87M float in CCHWF stock. Announcing a private placement of secured convertible notes, CCHWF stock rose.

    Was that private placement worth it?

    Columbia Care is one of the largest companies to cultivate, manufacture, and provide medical and adult-use cannabis products as well as related services with licenses in the United States and the EU. A total of 122 facilities are currently operated by CCHWF, including 92 dispensaries and 30 cultivation and manufacturing facilities.

    In addition to being a pioneer in medical marijuana, CCHWF continues to provide industry-leading products and services. CCHWF launched Cannabist, a retail brand that leverages proprietary technologies to provide a national cannabis dispensary network.

    Columbia Care announced last week that it has received commitments from investors for a private placement of worth $74,500,000 to issue 6.00% secured convertible notes due in 2025.

    • A syndicate of agents and CCHWF has entered into an agency agreement on June 17, 2021, that will conduct the CCHWF Offering in accordance with their best efforts.
    • CCHWF’s Offering was led by Canaccord Genuity, with ATB Capital Markets as co-lead agent.
    • Unless converted, redeemed or repurchased earlier, the Notes will be senior secured obligations of CCHWF and will accrue interest semi-annually in arrears.
    • There will be 154 CCHWF common shares converted to $1,000 of principal amount of Notes.
    • In other words, that will be the equivalent of approximately US$6.49 per Common Share of CCHWF.
    • There may be adjustments involved in the conversion.
    • The conversion price of the Notes represents a premium of approximately 25% over the closing price of the Common Shares on the NEO Exchange on June 17, 2021.
    • It is anticipated by CCHWF that the Offering will close on or about June 29, 2021.
    • In order for the deal to close, all formal documentation and regulatory approvals must be complete, including Canadian Securities Exchange and NEO Exchange approval.

    Acquisition by CCHWF:

    As reported by the company last week, Columbia Care (CCHWF) has agreed to acquire Medicine Man Denver, a vertically integrated cannabis serving Denver metro area since 2009. The acquisition of Medicine Man further consolidates CCHWF’s position as the world’s largest retailer, grower, and manufacturer of cannabis in Colorado.

  • What Has Been Raising The ENGlobal (ENG) Stock Higher Premarket?

    At last check, ENGlobal Corporation (ENG) shares were trading at $2.73, up 3.41% in premarket trading. During Friday’s session, the ENGlobal stock declined -2.58% to $2.64. The volume of shares traded for ENGlobal stock remained at 4.18 million versus 1.69 million during the past 50 days. ENG shares have increased by 153.85% over the last year, and they have decreased by -6.05% over the past week.

    ENG stock has lost -49.13% over the past three months, while it has gained 58.08% over the past six months. Furthermore, the company’s market cap is $95.20 million, and its shares outstanding total 27.56 million. Following the news it had been included in the Russell Microcap Index, ENG stock rose.

    What is the reasoning behind its inclusion in the Russell?

    ENGlobal provides renewable and conventional energy solutions nationwide as well as internationally. In addition to its Government Services business segment, ENG also operates two commercial business segments.

    ENGlobal last week reported that a preliminary list of additions posted by Russell on June 4, 2021, ENGlobal was selected to join the Russell Microcap Index following the 2021 Russell indexes annual reconstitution, effective after the US markets close on Friday, June 25, 2021.

    • By joining the Russell Microcap Index, which is for one year, investors are automatically included in the appropriate value and growth style indices.
    • In calculating Russell index membership, FTSE Russell considers primarily market capitalization and style factors.
    • Russell indices are widely used as benchmarks for active investment strategies and index funds by institutional investors and investment managers.
    • Russell’s US indexes are benchmarked against about $10.6 trillion in assets.
    • FTSE Russell, a significant global index provider, is the holder of Russell’s indexes.

    ENGlobal also completed delivery of the final 24 process modules needed to develop a complete hydrogen production facility in Hugoton, Kansas, on an 800 acre-plus site.

    • ENG’s customer, Seaboard Energy, will begin operation of the facility after several months of additional fabrication, construction, and start-up support. The facility will produce 6,500 barrels of renewable diesel fuel per day.
    • ENGlobal (ENG) has developed the world’s first hydrogen plant using HTCRTM (Haldor Topsoe Convection Reformer).
    • With Haldor Topsoe H2bridge technology, ENG can use renewable feedstocks to maximize use of renewable products and to reduce overall operating costs as well.
    • In addition to supplying modules, ENGlobal (ENG) provided engineering, detailed design, procurement, and automation services during the 18-month project.
  • Just Eat Takeaway.com (GRUB) stock surged in the premarket trading session; here’s why

    Just Eat Takeaway.com (GRUB) stock surged in the premarket trading session; here’s why

    In the premarket trading session, Just Eat Takeaway.com N.V. American Depositary Shares (GRUB) stock had surged by 1.08% to trade at $17.77 at last check. GRUB stock previously closed the session at a loss of -1.12% to $17.58. GRUB stock had moved down in the past week by -5.13%. In the past three and six months, the GRUB stock had shed -8.44% and -16.01% respectively. Furthermore, the company is currently valued in the market at $1.64 billion and has 93.35 million outstanding shares.

    Here’s what you need to know about GRUB stock

    GRUB stock is from an online food-pickup delivery company that provides an online and mobile platform where the restaurants and customers get food delivery and pick-up orders. The company has a platform usage and activity of approximately 300,000 local restaurants that make utility of its services and connect to customers and have are established in different cities with diners. The company offers mobile applications and websites which are operated through the main grubhub.com.

    The company offers a variety and range of offers for all sorts of customers; it has a corporate program for employees to order different foods and avail of different options. These different options include, catering, individual meals, group ordering, and this all can be done for a single online account.

    Also, it offers Grubhub for Restaurants, a responsive web application that can be accessed from PCs and cell phones, just as Grubhub-gave tablets; GH+ membership program to burger joints; conveyance administrations to cafés; retail location (POS) mix, which permits eateries to oversee Grubhub orders and update their menus straightforwardly from their current POS framework; and Website and versatile application plan and facilitating administrations for cafés, just as innovation and satisfaction administrations, including request transmission and client relationship the board devices. The organization was previously known as GrubHub Seamless Inc. furthermore, changed its name to Grubhub Inc. in February 2014. Grubhub Inc. was established in 1999 and is settled in Chicago, Illinois.

    The merger of Grubhub and Just Eat Takeaway.com can give a competition to Door Dash

    Previous week, the company and GRUB stock had its acquisition completed by Just Eat Takeaway.com (“Just Eat”) on 15th June 2021. The transaction was done through an all-share combination with 100% of the shares acquired. Just Eat is already on a strategic aim to expand its food delivery market in the United States especially in the digital segment as it transforms and replaces a portion of the retail phone-delivery services. The entry into the digital market is a strong justification for the company’s merger with Just Eat plc.

    Furthermore, the Enlarged Group of the Just Eat Takeaway has now established its presence in the United States, United Kingdom, The Netherlands, and Germany which allows it to have a share of the world’s four biggest markets.

    More details about the merger

    Due to this acquisition agreement, GRUB stock’s holders have been issued the Just Eat shares for their benefit and these have been issued as part of the agreement/contract. 30% of the company’s share capital as being represented through the Just Eat Takeaway.com ADS for the completion of the shares.

    The Just Eat Takeaway has this year already traded 3 times the sales which was done prior to the acquisition which when combined with the 2.5 times trade of Grubhub showcases a cheaper price-to-sales ratio than Door Dash. Some investors are giving this stock a chance to grow and believe it to be undervalued as compared to Door Dash which charges a premium on its stock.

  • Why Curaleaf (CURLF) Stock Fell Last Session?

    Share price of the leading lifestyle brand in cannabis and international provider of consumer products in cannabis, Curaleaf Holdings Inc (CURLF) fell -1.92 percent on Friday, closing at $13.310, and has been in the $13.100 to $13.700 range for the day. In the past month, shares of Curaleaf stock lost over -5.67%, with over 441.49K shares traded on average.

    On a three-month basis, CURLF stock fell over -17.33 while it averaged 689.45K shares traded. CURLF stock had a good 12 months, gaining 125.49% and reaching a high of $18.380 with a market cap of $8.11B. CURLF stock rose after entering into a strategic partnership.

    What was that partnership for?

    The Curaleaf Group is an international provider of cannabis consumer products that helps people make informed choices about cannabis. CURLF and its brands, including Curaleaf, Select, and Grassroots, provide exceptional medical, adult-use, and retail services, products, and customer support.

    Curaleaf recently announced a groundbreaking partnership between its Select label and legendary music and culture publication Rolling Stone.

    • In celebration of the symbiotic relationship between music and cannabis, CURLF joins the leading voices in music and popular culture.
    • Select and Rolling Stone will leverage their resources and experience to create innovative, leading-edge cannabis products together under the long-term partnership. Music is the quintessence of past, present, and future for Rolling Stone.
    • To begin with, CURLF’s Select products will be co-branded with Rolling Stone.
    • These include Select’s first pre-roll as well as “The Cliq,” its latest proprietary pod system.
    • Rolling Stone has handpicked three strains and flavor profiles to commemorate some of the most renowned artists and sounds that have defined music history.
    • In addition to the berry-forward “Overdrive” Sativa, the line also contains a complex and full-bodied “Reverb” Indica, and an invigorating “Phaser” Hybrid.

    Participation in confrencieses and events:

    This month, Curaleaf’s executive management team attended the following investor conferences and events:

    • Craig-Hallum’s 18th Annual Institutional Investor Conference hosted investor meetings with Curaleaf (CURLF) management on June 2, 2021.
    • Joseph Lusardi, CURLF’s Vice Chairman, and Executive Vice President participated in a US MSO panel at Piper Sandler’s 41st Annual Consumer Marketplace Conference on June 3, 2021. CURLF management also hosted individual and group meetings with investors.
    • Antonio Costanzo, Curaleaf International CEO, participated in a panel at Benzinga’s Cannabis Capital Conference on June 3, 2021.
  • Luokung Technology Corp. (LKCO) Stock Skyrockets Following eMapgo Acquisition and Chiangjiu Contract

    Luokung Technology Corp. (LKCO) Stock Skyrockets Following eMapgo Acquisition and Chiangjiu Contract

    Luokung Technology Corp. (LKCO) stock prices were up by a massive 22.16% as of the market closing on June 18th, 2021, bringing the price per share up to USD$2.37 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock surge by another 16.03%, bringing it up to USD$2.75.

    CCMC Designation Removed

    After a long and drawn-out battle, the company announced on June 15th, 2021 that the U.S. Department of Defense (DoD) had removed LKCO’s designation as a Communist Chinese Military Company (CCMC). Furthermore, stemming from the company’s omission from Executive Order 14032, LKCO and its shareholders no longer find themselves at the mercy of restrictions pursuant to Executive Order 13959. Executive Order 13959 is amended and superseded by Executive Order 14032.

    Settling of Lawsuit

    With this development, LKCO and the government Defendants have filed a joint stipulation that will see their lawsuit voluntarily dismissed, bringing it to a close. The ongoing lawsuit is in regard to the challenging of the CCMC designation. In light of the foregoing by the DoD, the company has regained eligibility for inclusion in the FTSE GEIS (Micro Cap) index. Re-inclusion into the index is expected upon the opening of markets on June 21st, 2021.

    Expanded Scope of LKCO

    The favorable outcome will be welcomed by both the company and its investors, with an additional update on continuing operations expected in the upcoming few weeks. The company is confident that the market potential for its spatial-temporal technology will only continue to grow, due to the explosive expansion of the scope of autonomous applications.

    Acquisition of eMapgo

    The company also recently announced the closing of its acquisition of eMapgo Technologies, the industry leader with its position in the Advanced Driving Assistance System. LKCO is hopeful that the combination of their core technology in conjunction with eMapgo’s ADAS and autonomous driving industry experience will translate into unprecedented growth.

    Chiangjiu Expressway Contract

    LKCO is a leading spatial-temporal intelligent big data services company, having established itself as a leading provider of LBS and HD maps for a myriad of industries in China. June 18th, 2021 saw the company announce the entering into a contract that will see LKCO deliver a new generation traffic control network for the Changjiu Expressway. As per the contract, the newly acquired EMG will be responsible for the development and implementation of a 3D real-life highway digital management system.

    Future Outlook for LKCO

    Rejuvenated by the removal of its looming CCMC designation, LKCO is poised to continue its previous trajectory of success. In light of its recent acquisition and expansion of it market footprint, the company is keen to usher in unprecedented growth. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Raven Industries Inc. (RAVN) stock surged in the premarket trading session; here’s why

    Raven Industries Inc. (RAVN) stock surged in the premarket trading session; here’s why

    In the premarket trading session, Raven Industries Inc.’s (RAVN) stock had surged by 47.23% to $56.86 at the last check. RAVN stock previously closed the session of Friday at a loss of -5.34% to $38.62. The RAVN stock volume traded 0.48 million shares. In the past year up to date, RAVN shares have jumped by 84.87%, however, in the past week, the shares moved plunged by -11.16%. In the past three and six months, the RAVN stock has gained 5.78% and added 16.50% respectively. Furthermore, the company is currently valued in the market at $1.47 billion and has 36.04 million outstanding shares.

    Here’s what you need to know about Raven Industries

    Raven Industries Inc. is a tech company that deals with the industrial sector along with many other sectors including agricultural, building and constructions, airline, defense, and other markets worldwide. The company provides various products to the customers related to technology.

    The segments through which the company works include the Engineered Films, Aerostar and Applied Technology.

    The Applied Tech segment focuses on the designing, manufacturing, marketing, and selling services related to the agriculture field as well as the information management tools. These tools are used by the farmers to enhance their farming yield.

    Its items incorporate application controls, GPS-direction controlling frameworks, field PCs, programmed blast controls, machine computerization, data the board apparatuses, and infusion frameworks, just as Slingshot, a correspondences stage for its agriculture retailers, custom implements, and undertaking homesteads; and administrations involve high-velocity in-field Internet network and cloud-based information the executives. This section offers its items to unique hardware producers and through post-retail appropriation accomplices.

    This Engineered Films segment focuses on the production of films made of plastic as well as a specific kind of sheeting that is used for geo-membrane, construction work, and industrial applications. The company also offers customized design creation and labor services to install these films and sheets. The products are sold through a direct channel of end customers and independent third-party distributors.

    The Aerostar segment offers high-altitude stratospheric platforms, technical services, and radar systems to provide research, communications, and situational awareness capabilities to governmental and commercial customers in the aerospace and defense, and commercial lighter-than-air markets. Raven Industries, Inc. was incorporated in 1956 and is headquartered in Sioux Falls, South Dakota.

    Raven Industry is being acquired by CNH industrial

    The RAVN stock and company are being sold through a deal agreement today (21 June 2021) with the CNH industrial. The CNH industrial works as a global leader in the capital goods sector. The CNH industrial (“CNHI”) is mainly known for creating agricultural, commercial, construction, firefighting, defense vehicles, and earth-moving machinery. So based on this background of the company, it is apparent that CNHI is expanding and strengthening its position in the agricultural equipment business.

    Further details of the deal

    In retrospect, the company has already initiated a business restructuring and transforming operation where it is preparing to spin-off its trucks, business, and engine operations.

    The deal has an enterprise value of $2.1 billion which is going to be paid to RAVN stock through a $58 per share price for a 33.6% premium based on the 4-week weighted volume of average stock price.

  • X4 Pharmaceuticals, Inc (XFOR) Stock Continues Downward Trend Since Disclosure of Positive Preliminary Mavorixafor Data

    X4 Pharmaceuticals, Inc (XFOR) Stock Continues Downward Trend Since Disclosure of Positive Preliminary Mavorixafor Data

    X4 Pharmaceuticals, Inc. (XFOR) stock prices were down by 8.40% as of the market closing on June 18th, 2021, bringing the price per share down to USD$7.42 at the end of the trading day.

    Mavorixafor Clinical Trial

    June 11th, 2021 saw the company announce positive preliminary efficacy and safety data from the ongoing Phase 1b clinical trial of movorixafor. The lead candidate was being administered in conjunction with ibrutinib to patients with Waldenstrom’s macroglobulinemia exhibiting MYD88 and CXCR4 mutations. The findings were published in a post at the European Hematology Association 2021 Annual Congress.

    Promising Start

    The promising results of the ongoing trial already exhibit robust decreases in IgM levels, despite still being in the low- to mid-dose ranges of the treatment. This crucial signal of clinical response shows the potential benefit of administering mavorixafor in combination with ibrutinib. The combined therapy has demonstrated adequate tolerability and promising results across various pharmacodynamic parameters, including increases in total hemoglobin and mobilization of white blood cells. Longer-term data and an expanded dataset from the trial are expected for later in the fiscal year 2021.

    Scope of Trial

    With ibrutinib having substantially addressed the treatment of Waldenstrom’s macroglobulinemia, the company continues to observe a significant unmet clinical need for patients with concurrent CXCR4 and MYD88 mutations. The encouraging preliminary safety and efficacy data from the ongoing combined treatment trials has significantly advanced treatment in this challenging patient population.

    Details of the Trial

    The Phase 1b clinical trial had 8 patients enrolled as of April 15th, 2021, with a median duration of treatment of 156 days. The data presenting primarily concerns patients from Cohort A, who were administered low- to mid-range doses of mavorixafor and ibrutinib. Four of the patients were treated for more than six 28-day cycles.

    Preliminary Results

    Reductions in serum IgM were reported by 100% of the patients that were a part of the trial, with none of them exhibiting a progression of the disease while undergoing treatment. All of the patients who exhibited below normal baseline hemoglobin level reported increases while being administered the treatment, with a median change in hemoglobin of more than 20 g/L. This closes the gap between patient’s and normal levels of hemoglobin, suggesting a reduction in cancer burden in the bone marrow.

    Future Outlook for XFOR

    Armed with the recent success of its clinical trial, XFOR is poised to continue its trajectory of success as it pushes its flagship treatment through to commercialization. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

    Tags: X4 Pharmaceuticals, X4 Pharma, XFOR, XFOR stock, biopharmaceutical, biopharma, healthcare, mavorixafor

  • How The Idera (IDRA) Stock Jumped 5%?

    Idera Pharmaceuticals Inc. (IDRA) shares last traded at $1.22 in after-hours trading, rising 5.17%. IDRA’s stock closed at $1.16 the last session, declining -5.69% or $0.07. The stock fluctuated between $1.16 and $1.23 throughout the day. Shares were exchanged for 1.12 million, less than their 50-day volume of 1.48 million or their year-to-date volume of 2.15 million.

    Its stock has gone down -11.45% over the past one week and declined -37.97% in the past year. A total of -75.05% has been lost over the last six months and a total of -41.41% over the last three months. As the IDRA stock rose in absence of current news, we can then point to recent developments to provide a more thorough understanding of IDRA.

    Developments recently occurred at IDRA?

    In its lead development program, Idera works with early immunotherapy researchers and leverages its experience creating proprietary immunology platforms to prime the immune system to fight cancer more effectively with the goal of ultimately treating more people with immunotherapy. As part of its continued focus on oncology and rare disease drug candidates, Idera also continues to acquire, develop, and commercialize drugs for populations with small, well-defined patient populations with unmet needs.

    Recently, Idera announced that it would no longer be pursuing ILLUMINATE-301 and also provided a corporate update.

    • The purpose of that study was to compare tilsotolimod with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, and to determine its overall survival (OS).
    • In March 2021, IDRA reported the trial failed to meet its primary endpoint of objective response rate (ORR).
    • IDRA will publish the complete results from study in the near future.
    • IDRA has reviewed the full data set for ILLUMINATE-301 and consulted with our Study Steering Committee and Bristol Myers Squibb (BMS) regarding the next steps for the trial since receiving the disappointing ORR results.
    • Vincent Milano, chief executive officer of Idera, stated, We are of the opinion that the combined use of both tilsotolimod and ipilimumab is unlikely to achieve a statistically significant improvement in OS over either drug alone. All the patients and investigators deserve my personal thanks for their efforts.
    • Milano said that IDRA’s ILLUMINATE-206 is still enrolling and treating patients.
    • In this Phase 2 study, IDRA’s tilsotolimod is paired with BMS’ nivolumab and ipilimumab.
    • In this trial, AbbVie will receive a study drug that will support their study for patients with squamous cell carcinoma of the head and neck and for patients with Microsatellite-stable colorectal cancer.
    • IDRA is actively identifying and securing new assets for development or commercialization, Mr. Milano stated, as the company looks to the future.
    • The IDRA team has a proven track record and is passionate about helping patients, which can be beneficial in developing promising compounds.

    Management changes:

    IDRA also announced that Elizabeth Tarka, M.D., Chief Medical Officer for the Company since July 2019, will depart the Company on May 28, 2021. Tarka will continue to serve as a consultant to Idera (IDRA). According to Mr. Milano, Liz helped IDRA deliver ILLUMINATE-301 and has contributed to many other initiatives over the past two years.

  • Why The Birks Group (BGI) Stock Was Up In Afterhours Trades?

    Birks Group Inc. (BGI) gained 6.84% to $2.50 during after-hours trading Friday. Shares of BGI were down 3.31 percent at $2.34 during the previous trading session. During the period, the company’s shares ranged from $2.19 to $2.49. The firm traded 0.29 million shares, below the daily average of 1.07 million equity shares it traded over the past hundred days. As of the last five days, BGI’s shares fell by 17.02 percent, but in the previous month they went down by 15.52 percent.

    What happened at BGI?

    Birks Group manufactures jewelry in addition to operating jewellery stores. They are a leading manufacturer and retailer of fine jewellery, watches, and gifts in Canada. In 2021, BGI plans to have 26 stores operating under the Maison Birks banner in most Canadian metropolitan areas, as well as a retail location in Calgary operating under the Brinkhaus banner, one in Vancouver operating under Graff and one in Vancouver operating under the Patek Philippe banner.

    The On Thursday, the Birks Group released its financial results for the fiscal year that ended on March 27, 2021.

    • The figures presented here are all in Canadian dollars.
    • Because the BGI had to close numerous stores at intermittent times throughout the year due to government restrictions, its financial results were significantly impacted by the COVID-19 pandemic during the fiscal year ended March 27, 2021.
    • Birks Group’s net sales dropped to $143.1 million with a decrease of $26.3 million, or 15.5%, compared to the fiscal year 2020.
    • COVID-19 negatively impacted BGI’s gross profit of $56.4 million, a decrease of $8.1 million, or 12.6%, compared to fiscal 2020.
    • For BGI, a gross profit percentage of 39.4% represents an increase of 130 basis points over fiscal 2020’s gross profit percentage of 38.1%.
    • As a result of its proactive management of the pandemic, Birks Group effectively controlled costs despite declining sales and gross profits volumes.
    • In fiscal 2021, total operating expenses fell by $11.8 million 16.6% over fiscal 2020 to $59.2 million.

    What’s still impacting BGI?

    Birks Group (BGI)’s fiscal 2021 EBITDA totaled $2.6 million, an increase of $4.3 million over the $1.7 million negative EBITDA for fiscal 2020. In June 2021, 20 of the BGI’s 29 stores were open, albeit with reduced hours of operation. As a result of a government order, BGI’s nine remaining stores in Ontario will be closed until at least July 6, 2021.

  • COMSCORE, Inc (SCOR) stock turnaround in the after-hours on Friday?

    COMSCORE, Inc (SCOR) stock turnaround in the after-hours on Friday?

    COMSCORE Inc. (SCOR) shares surged 12.68% in after-hours on Friday, June 18, 2021, and close the week at $4.62 per share. Earlier in the morning session, SCOR’s stock lost 5.09% to close Friday’s normal session at $4.10 per share. SCOR shares have risen 23.12% over the last 12 months, and they have moved down 11.06% in the past week. Over the past three months, the stock has gained 12.02%, while over the past six months, it has plunged 95.24%.

    Comscore and Viant partnership

    On June 16, 2021, Comscoresigned a partnership agreement with Viant Technology Inc.

    The contextual-based partnership enables Viant’s advertisers to leverage Comscore’s cookie-free targeting solutions, including brand protection, contextual relevance, keyword targeting, and Comscore’s latest innovation, Predictive Audiences, which transforms audience targets into privacy-friendly contextual signals.

    Exclusive Multiyear TV Measurement Deal with Octagon

    On June 15, 2021, Comscoreand Octagon, signed a multi-year agreement to utilize Comscore’s TV data for planning, buying and measurement. Comscore will be the retained provider of U.S. television intelligence to Octagon, helping to inform decisions for their clients on TV rights, branded content engagements and marketing opportunities.

    WarnerMedia joined Comscoretrials

    On June 9, 2021, Comscoreannounced that WarnerMedia is the first national programmer to formally participate in Comscore’s National Addressable TV programmer trials. WarnerMedia has executed national addressable campaigns across multiple MVPD platforms, with detailed aggregated measurement powered by Comscore.

    Comscore new contract with Capitol Broadcasting

    On June 7, 2021, Comscoresigned a new agreement with Capitol Broadcasting to provide Comscore’s industry-leading local TV measurement, including for WRAL & WRAZ in Raleigh, NC.

    Upcoming presentation ofAnnual State of OTT Webinar on latest usage trends

    Comscore is going to present the annual State of OTT Webinar on June 24 at 2pm ET. The webinar will feature Senior Director of Product Management James Muldrow and Senior Vice President of Commercial Tara Gotch, to discuss how U.S. consumers have engaged with OTT content and devices during the 2020 pandemic and beyond.

    TV viewing engagement report for the week ending May 23, 2021

    On June 3, 2021, Comscorereleased the top broadcast and cable television programs for viewer engagement for the week ending May 23, 2021.

    The results are available on the Comscore website.

    Comscore partnership with Spiketrap

    On June 2, 2021, Comscorepartnered with Spiketrap, to expand Comscore’s industry-leading Predictive Audiences cookieless targeting solution specifically for gaming audiences. The partnership is a major step forward for advertisers seeking to engage with gaming audiences in a privacy-forward, cookie-free manner.

    Conclusion

    Well, as of this writing there is no recent news that could justify SCOR mix performance on Friday. the positive performance can be linked with recent past developments which hare all positive but we are unsure why did its loss in the morning session on Friday.